SEBI Ne Thok Diya! Par Drugs Ka ₹95 Crore Deal Atki, Promoter Firm Ke Saath Hogi Bade Check-Up

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
SEBI Ne Thok Diya! Par Drugs Ka ₹95 Crore Deal Atki, Promoter Firm Ke Saath Hogi Bade Check-Up
Overview

Arre yaar, Par Drugs ke investors ke liye buri khabar hai! SEBI, India ka market regulator, ne confirm kar diya hai ki Par Drugs & Chemicals ka **₹95 Crore** ka slump sale ab nahi hoga. Yeh deal promoter firm Phal-Jig Fine Chemicals ke saath hone wali thi, but SEBI abhi valuation aur governance ka hisaab kitaab check kar raha hai. Iss wajah se stock price bhi gir gaya hai.

SEBI Ne Lagayi Deal Par Rok!

SEBI ne Par Drugs ko bada jhatka diya hai. Unka ₹95 Crore ka core business Phal-Jig Fine Chemicals Pvt Ltd. ko transfer karne ka jo deal tha, woh ab confirm ho gaya hai blocked. SEBI ne pehle September 2025 mein is par interim order diya tha, but Par Drugs unke initial findings ko sahi se counter nahi kar paaya. Yeh move public shareholders ko bachane aur market ko saaf rakhne ke liye hai.

Kya Hai Regulator Ka Concern?

SEBI ki investigation main deal ka valuation, shareholders ko clear information mili ya nahi, aur voting process sahi tha ya nahi, yeh sab cheezein check ho rahi hain. Ek complaint mein kaha gaya tha ki yeh slump sale laws ke khilaaf jaa sakta hai aur public shareholders ko nuksan pahuncha sakta hai. Abhi Par Drugs ka P/E ratio sirf 7.7 hai, jo ki industry ke peers ke 45.82 ke average P/E ratio se kaafi kam hai. Iska matlab ya toh market pehle se hi risk factor dekh raha hai, ya company under-valued hai. SEBI aise promoter deals par kadi nazar rakhta hai.

Market Reaction Aur Investors Ki Chinta

Market mein bhi is news ka bura asar dikh raha hai. Jab se yeh deal announce hui thi, Par Drugs ki market cap lagbhag 70% gir gayi hai. Investors ko transaction ki fairness aur shareholder value par impact ko lekar chinta hai. SEBI promoter-driven deals par zyada dhyaan de raha hai, especially agar valuation mein gadbad ho ya assets kam ho rahe hon. Yeh ongoing investigation Par Drugs ke liye uncertainty badha raha hai aur stock performance bhi dikh raha hai, jaise ki last one month mein -12.1% aur one year mein -14.93% ka fall aaya hai.

Deal Kab Tak Atki Rahegi?

Toh abhi ke liye, ₹95 Crore ka yeh slump sale indefinitely halt ho gaya hai. Business transfer agreement February 2025 mein sign hua tha, par jab tak SEBI apna final report nahi deta, kuch nahi ho sakta.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.